Full-Time

Associate Director/Director of IT

Posted on 9/11/2026

Kura Oncology

Kura Oncology

201-500 employees

Clinical-stage oncology company develops targeted therapies

Compensation Overview

$186k - $259k/yr

+ Annual target bonus + Equity + Stock options + ESPP

San Diego, CA, USA

In Person

Bachelor's

Category
IT Operations
Required Skills
LLM
Incident Response
Forecasting
Risk Management

Get referred to Kura Oncology

See people who can refer or advise you

Requirements
  • A bachelor's degree in a related technical or business discipline is required.
  • A minimum of 8–10 years of progressive experience in IT leadership roles, including at least 5 years in management positions, is required.
  • Demonstrated experience developing and implementing enterprise-wide IT strategies that drive business value.
  • Understanding of current security practices and standards for mid-size enterprise IT.
  • Extensive experience in portfolio management, including portfolio management tools and methodologies.
  • Strong background in change management, with demonstrated success managing complex organizational changes.
  • Expertise in IT financial management, including budgeting, forecasting, cost optimization techniques, and SOX reporting.
  • In-depth knowledge of IT governance frameworks such as COBIT and ITIL, with experience implementing governance structures.
  • Ability to communicate effectively with C-level executives, board members, and diverse stakeholder groups.
  • Strong analytical skills and the ability to translate complex technical concepts into business terms.
  • Experience with digital transformation initiatives and emerging technologies such as cloud, artificial intelligence, and the Internet of Things.
  • A track record of building and leading high-performing teams in a fast-paced, dynamic environment.
  • Strong negotiation skills and experience managing vendor relationships and contracts.
  • Commitment to continuous learning and staying current with industry trends and best practices.
  • Ability to make decisions for assigned programs or functional areas, balance priorities, resolve routine challenges, and escalate high-impact or cross-functional decisions as needed.
  • Ability to facilitate cross-functional coordination for assigned programs or initiatives, ensuring alignment and timely execution of deliverables.
Responsibilities
  • Develop, implement, and continuously refine a comprehensive IT strategy in partnership with the Head of IT and functional stakeholders to support overall business objectives.
  • Integrate emerging technologies and lead digital transformation initiatives aligned with the company's strategic vision.
  • Establish and maintain an IT portfolio management framework, including tools and processes for project prioritization, resource allocation, and performance tracking.
  • Conduct regular portfolio reviews to balance risk, value, and strategic alignment.
  • Collaborate with business units and system owners to identify and prioritize IT initiatives that drive business value.
  • Implement and maintain security policies based on company roadmap initiatives and business goals.
  • Evaluate system vulnerabilities and conduct regular audits, risk assessments, and compliance checks to ensure security standards are met.
  • Coordinate with the incident response team on security incidents, investigate root causes, and implement corrective measures.
  • Develop and execute the company's enterprise artificial intelligence strategy and roadmap, identifying opportunities for artificial intelligence, generative artificial intelligence, and automation.
  • Establish and maintain an artificial intelligence governance framework covering appropriate use, data privacy, information security, regulatory compliance, intellectual property, risk management, and responsible artificial intelligence practices.
  • Lead the evaluation, selection, and implementation of enterprise artificial intelligence platforms, tools, and capabilities.
  • Identify, prioritize, and develop high-value artificial intelligence use cases across the organization, establishing business outcomes, ownership, success criteria, and measures of value.
  • Collaborate with Information Security, Legal, Compliance, Quality, and business stakeholders to assess and manage risks associated with artificial intelligence technologies.
  • Develop policies, standards, and procedures governing the responsible use of generative artificial intelligence and other artificial intelligence technologies.
  • Drive responsible artificial intelligence adoption through employee education, training, communications, and change management programs.
  • Ensure artificial intelligence solutions supporting GxP or other regulated business processes are assessed, documented, validated, and governed with Quality and applicable Business System Owners.
  • Develop and execute change management strategies for major IT initiatives and organizational transformations.
  • Create and maintain a change management framework and train the IT team on its effective use.
  • Lead the development and execution of multichannel IT communication plans.
  • Establish feedback mechanisms to measure the effectiveness of change initiatives and communications.
  • Collaborate with Human Resources and other departments to align IT changes with broader organizational change efforts.
  • Ensure IT systems used in GxP-regulated processes are implemented, validated, and maintained according to regulatory standards and company processes.
  • Collaborate with Business Systems Owners, IT, and Quality teams to develop and execute validation deliverables, including IQ, OQ, and PQ.
  • Monitor system changes for compliance with change control procedures and regulatory standards.
  • Support internal and external audits, including audits conducted by regulatory authorities such as the FDA and EMA.
  • Prepare compliance documentation and provide evidence for GxP audits and inspections.
  • Follow up on audit findings and assist with remediation plans to close gaps.
  • Assess and refine the IT operating model to improve efficiency, effectiveness, and alignment with business needs.
  • Establish and maintain IT governance frameworks and decision-making processes for cross-functional steering committees.
  • Develop and oversee IT performance metrics and scorecards to drive continuous improvement.
  • Oversee development and management of the annual IT budget with the Head of IT.
  • Implement financial management processes for the IT team.
  • Develop IT financial forecasts based on technology trends and business growth projections.

Kura Oncology develops precision medicines for cancer, focusing on small-molecule drugs that target tumors with specific genetic mutations. It is in the clinical-stage, researching and developing its own drug candidates to eventually bring them to market. Its leading candidate, ziftomenib, blocks the menin-KMT2A/MLL protein interaction, offering a targeted approach for genetically defined acute myeloid leukemia (AML). The company is also pursuing tipifarnib for head and neck squamous cell carcinoma (HNSCC) and other solid tumors. By collaborating with academic institutions and other biotech companies, Kura Oncology expands its pipeline and advances therapies through clinical trials. The goal is to deliver effective, targeted cancer treatments for patients with unmet medical needs and to grow its portfolio through research, development, and partnerships.

Company Size

201-500

Company Stage

IPO

Headquarters

San Diego, California

Founded

2014

Get referred to Kura Oncology

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 KOMZIFTI revenue rose 57% sequentially to $9.1 million.
  • Cash reached $519 million on June 30, 2026, plus $180 million Kyowa Kirin payments.
  • Darlifarnib showed 44% RCC response and KRAS shrinkage in 2026 studies.

What critics are saying

  • Syndax Revuforj and J&J bleximenib pressure Kura before KOMET-017 2028.
  • Q2 2026 revenue was $9.1 million against $68.3 million net loss.
  • If KOMET-017 misses, Kura loses its AML growth engine and valuation collapses.

What makes Kura Oncology unique

  • KOMZIFTI became FDA-approved on 2025-11-13 for R/R NPM1-mutated AML.
  • Kura captured majority new starts in Q2 2026 menin-inhibitor NPM1 AML.
  • Kyowa Kirin partnership funds global development and commercialization through 2028.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Holidays

Paid Paternity/Maternity Leave

Home Office Stipend

Lifestyle Spending Stipend

Commuter Stipend

Wellness Program

Gym Membership

Company Social Events

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

1%

2 year growth

0%
Yahoo Finance
Aug 26th, 2026
Kura Oncology CEO invests $2.35M in company shares, stock surges 50%

Kura Oncology shares surged on 25 August after CEO Troy Wilson purchased 100,000 shares for approximately $1.24 million, following a $1.11 million investment days earlier. The stock has risen more than 50% from recent lows. Wilson's One Fish Two Fish Revocable Trust now holds 479,194 shares. The purchases signal confidence as the company's share price advances, though insider buying doesn't guarantee future gains. The rally follows the commercial launch of KOMZIFTI, an FDA-approved treatment for certain acute myeloid leukaemia patients. The drug generated $9.1 million in net revenue last quarter, up 57% sequentially, with new patient starts growing 35% to about 115. Kura Oncology expects $180 million in additional collaboration payments from Kyowa Kirin.

Yahoo Finance
Aug 25th, 2026
Kura Oncology CEO buys 100,000 shares for $1.2M amid 62% annual stock gain

Troy Edward Wilson, CEO of Kura Oncology, purchased approximately 100,000 shares of the company's common stock for $1.2 million on 24 August 2026, according to an SEC Form 4 filing. The shares were acquired at $12.39 each. The transaction increased Wilson's total stock position by 9%, bringing his combined direct and indirect holdings to approximately 1.2 million shares valued at $15.06 million. Following the purchase, Wilson holds roughly 435,000 shares directly and 779,000 shares indirectly through the One Fish Two Fish Revocable Trust and the Lorax Charitable Remainder Unitrust. Kura Oncology, a clinical-stage biopharmaceutical company based in San Diego, has a market capitalisation of $1.1 billion. The company reported trailing twelve-month revenue of $77.2 million and a net loss of $296.8 million.

Yahoo Finance
Aug 18th, 2026
Kura Oncology up 14.5% on ziftomenib resistance data and $20.87M Q2 revenue

Kura Oncology's stock rose 14.5% following second-quarter results and publication of preclinical data on its FDA-approved menin inhibitor ziftomenib in the journal Blood. Revenue increased to $20.87 million, though net loss widened to $68.33 million. The Blood study showed ziftomenib retained activity against certain resistance-linked MEN1 mutations in leukaemia models, strengthening scientific confidence in the therapy. The drug is marketed as KOMZIFTI for relapsed or refractory NPM1-mutated AML and is being investigated for broader oncology applications. Despite the positive data, Kura remains unprofitable with substantial quarterly losses. Analyst revenue projections for 2029 range widely, from consensus estimates around $353 million to more optimistic forecasts of $861.5 million, reflecting uncertainty about the company's commercial trajectory.

Yahoo Finance
Aug 13th, 2026
Kura Oncology captures majority of NPM1-mutant AML market share in second quarter despite late entry

Kura Oncology reported $9.1 million in net product revenue for COMZIFTI in Q2 2026, exceeding internal expectations. The company captured majority share of new patient starts in the relapsed/refractory NPM1-mutant AML menin inhibitor market within its second full commercial quarter, despite being second to market. Management attributes the rapid adoption to the product's differentiated profile, including predictable safety and dosing convenience. Physician-initiated combination use accounted for approximately 40% of new patient starts. The company has achieved over 90% engagement with top-priority AML accounts and secured market access covering over 95% of lives. Kura maintained collaboration revenue guidance of $45 million to $55 million for 2026. The pivotal KOMET-017 Phase 3 trial remains on track for top-line results in 2028.

Associated Press
Aug 12th, 2026
Kura Oncology's KOMZIFTI generates $9.1M in Q2, up 57% as it captures majority share in R/R NPM1-mutant AML market

Kura Oncology reported second quarter 2026 financial results, with KOMZIFTI generating $9.1 million in net product revenue, up 57% from the first quarter. The drug also achieved approximately 115 new patient starts, a 35% increase over the previous quarter. KOMZIFTI secured majority share of new patient starts in the relapsed or refractory NPM1-mutant AML menin inhibitor class after two full quarters on the market. The company reported more than 250 total prescriptions in the second quarter, up 59% from the first quarter. Research and development expenses totalled $61.9 million, whilst selling, general and administrative expenses reached $31.8 million. Net loss for the quarter was $68.3 million. As of 30 June 2026, Kura held $519.0 million in cash, cash equivalents and short-term investments, plus $180 million in anticipated collaboration payments from Kyowa Kirin.